Homology Medicines (FIXX) Stock Price, News & Analysis

Company Overview

Homology Medicines, Inc., a genetic medicines company, focuses on transforming the lives of patients suffering from rare genetic diseases in the United States. The company offers proprietary platform is designed to utilize its human hematopoietic stem cell derived adeno-associated virus vectors (AAVHSCs) to deliver genetic medicines in vivo either through a nuclease-free gene editing mobility, gene therapy or for various genetic disorders. Its earlier stage product candidates comprising HMI-202, an investigational gene therapy which completed IND-enabling studies for the treatment of metachromatic leukodystrophy; and HMI-104 which completed IND-enabling studies. Homology Medicines, Inc. was incorporated in 2015 and is headquartered in Bedford, Massachusetts.

Key Stats

• Today's Range: N/A
• 50-Day Range: $0.33 to $16.82
• 52-Week Range: N/A
• Volume: 22,300 shs
• Average Volume: 390,307 shs
• Market Capitalization: $978.01 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Homology Medicines Stock Analysis - MarketRank™

Homology Medicines scored higher than 13% of companies evaluated by MarketBeat, and ranked 874th out of 921 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for Homology Medicines.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Homology Medicines are expected to grow in the coming year, from ($0.75) to ($0.70) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Homology Medicines is -8.58, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Homology Medicines is -8.58, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: N/A
• Short Interest Level: N/A

Short Interest

There is no current short interest data available for FIXX.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Homology Medicines does not currently pay a dividend.

Dividend Growth

Homology Medicines does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 4.8 / 5
• Environmental Score: -0.33

Short Interest

There is no current short interest data available for FIXX.

News and Social Media

• Score: 0.0 / 5
• News Sentiment: N/A

Search Interest

Only 1 people have searched for FIXX on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

Company Ownership

• Score: 0.8 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Homology Medicines insiders have not sold or bought any company stock.

Percentage Held by Insiders

16.10% of the stock of Homology Medicines is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

Only 31.32% of the stock of Homology Medicines is held by institutions.

FIXX Stock Analysis - Frequently Asked Questions

How were Homology Medicines' earnings last quarter?

Homology Medicines, Inc. (NASDAQ:FIXX) issued its quarterly earnings results on Monday, November, 15th. The company reported ($0.27) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.30) by $0.03. The business had revenue of $1.68 million for the quarter, compared to analysts' expectations of $0.63 million. Homology Medicines had a negative net margin of 4,779.31% and a negative trailing twelve-month return on equity of 102.52%.

When did Homology Medicines' stock split?

Homology Medicines shares split before market open on Wednesday, March 20th 2024.The 2-1 split was announced on Wednesday, March 20th 2024. The newly issued shares were payable to shareholders after the market closes on Wednesday, March 20th 2024. An investor that had 100 shares of stock prior to the split would have 200 shares after the split.

When did Homology Medicines IPO?

Homology Medicines (FIXX) raised $100 million in an initial public offering (IPO) on Wednesday, March 28th 2018. The company issued 6,700,000 shares at $14.00-$16.00 per share. BofA Merrill Lynch, Cowen and Evercore ISI served as the underwriters for the IPO and BTIG was co-manager.

What other stocks do shareholders of Homology Medicines own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Homology Medicines investors own include Editas Medicine (EDIT), NVIDIA (NVDA), Enovix (ENVX), Luminar Technologies (LAZR), Advanced Micro Devices (AMD), Ginkgo Bioworks (DNA) and Tesla (TSLA).

Company Calendar

• Last Earnings: 11/15/2021
• Today: 8/07/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: N/A
• Current Symbol: NASDAQ:FIXX
• CIK: 1661998
• Web: www.homologymedicines.com
• Phone: (781) 301-7277
• Fax: N/A
• Employees: 7
• Year Founded: 2015

Profitability

• EPS (Trailing Twelve Months): ($1.96)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$112.96 million
• Net Margins: -4,779.31%
• Pretax Margin: -7,532.87%
• Return on Equity: -102.52%
• Return on Assets: -74.91%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 7.25
• Quick Ratio: 7.25

Sales & Book Value

• Annual Sales: $1.16 million
• Price / Sales: 0.00
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.26 per share
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 58,130,000
• Free Float: 48,774,000
• Market Cap: $978.01 million
• Optionable: Optionable
• Beta: -0.10